REGENXBIO Inc. (NASDAQ:RGNX) Receives $35.27 Average PT from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $35.27.

Several research analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. HC Wainwright reduced their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Raymond James restated an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th.

REGENXBIO Stock Performance

REGENXBIO stock opened at $8.29 on Monday. REGENXBIO has a 52 week low of $7.14 and a 52 week high of $28.80. The firm has a market capitalization of $410.73 million, a PE ratio of -1.65 and a beta of 1.28. The business’s 50-day simple moving average is $9.03 and its 200-day simple moving average is $10.71.

Institutional Trading of REGENXBIO

A number of large investors have recently bought and sold shares of the stock. Amalgamated Bank boosted its stake in shares of REGENXBIO by 9.9% in the 2nd quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,227 shares in the last quarter. FMR LLC lifted its holdings in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. Arizona State Retirement System boosted its position in REGENXBIO by 20.6% in the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,997 shares in the last quarter. nVerses Capital LLC boosted its position in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 2,200 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.